LLY

1,027.35

+0.07%↑

JNJ

228.11

-1.06%↓

ABBV

211.5

-0.66%↓

UNH

382.83

-1.91%↓

AZN

185.91

-0.62%↓

LLY

1,027.35

+0.07%↑

JNJ

228.11

-1.06%↓

ABBV

211.5

-0.66%↓

UNH

382.83

-1.91%↓

AZN

185.91

-0.62%↓

LLY

1,027.35

+0.07%↑

JNJ

228.11

-1.06%↓

ABBV

211.5

-0.66%↓

UNH

382.83

-1.91%↓

AZN

185.91

-0.62%↓

LLY

1,027.35

+0.07%↑

JNJ

228.11

-1.06%↓

ABBV

211.5

-0.66%↓

UNH

382.83

-1.91%↓

AZN

185.91

-0.62%↓

LLY

1,027.35

+0.07%↑

JNJ

228.11

-1.06%↓

ABBV

211.5

-0.66%↓

UNH

382.83

-1.91%↓

AZN

185.91

-0.62%↓

Strona główna・Stock List・Roivant Sciences Ltd

Roivant Sciences Ltd

Closed

SectorHealthcare

32.4 14.85

Buy Sell

Overview

Share price change

24h

Current

Min

28.21

Max

32.78

Key metrics
By Trading Economics
Income	-200M -314M
Sales	428K 2M
Profit margin	-15,692.896
Employees	750
EBITDA	-132M -290M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+26.52% upside

Market Stats
By TradingEconomics
Market Cap	4.9B 20B
Previous open	17.55
Previous close	32.4

News Sentiment

By Acuity

11%

89%

13 / 345 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

11 / 11.18 Support & Resistance

Roivant Sciences Ltd Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

20 maj 2026, 23:31 UTC

Hot Stocks

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20 maj 2026, 22:52 UTC

Major Market Movers

Osisko Shares Fall on Planned Convertible Notes Offering

20 maj 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20 maj 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20 maj 2026, 23:44 UTC

Earnings

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20 maj 2026, 23:35 UTC

Market Talk

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20 maj 2026, 23:30 UTC

Market Talk

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20 maj 2026, 23:17 UTC

Market Talk

Global Equities Roundup: Market Talk

20 maj 2026, 23:17 UTC

Market Talk

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20 maj 2026, 23:15 UTC

Market Talk

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20 maj 2026, 23:14 UTC

Earnings

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20 maj 2026, 23:02 UTC

Market Talk

KMD Brands Faces Two Testing Hurdles -- Market Talk

20 maj 2026, 22:57 UTC

Market Talk

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20 maj 2026, 22:57 UTC

Market Talk

Global Energy Roundup: Market Talk

20 maj 2026, 22:57 UTC

Market Talk

Global Equities Roundup: Market Talk

20 maj 2026, 22:51 UTC

Market Talk

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20 maj 2026, 22:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20 maj 2026, 22:27 UTC

Market Talk

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20 maj 2026, 22:14 UTC

Market Talk

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20 maj 2026, 22:10 UTC

Earnings

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20 maj 2026, 22:00 UTC

Earnings

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20 maj 2026, 21:38 UTC

Earnings

Acquisitions, Mergers, Takeovers

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20 maj 2026, 21:27 UTC

Earnings

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20 maj 2026, 21:20 UTC

Earnings

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20 maj 2026, 21:19 UTC

Earnings

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20 maj 2026, 21:18 UTC

Earnings

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20 maj 2026, 21:17 UTC

Earnings

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20 maj 2026, 21:17 UTC

Earnings

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20 maj 2026, 21:17 UTC

Earnings

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20 maj 2026, 21:16 UTC

Earnings

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Peer Comparison

Price change

Roivant Sciences Ltd Forecast

Price Target

By TipRanks

26.52% upside

12 Months Forecast

Average 35.69 USD 26.52%

High 41 USD

Low 29.5 USD

Based on 8 Wall Street analysts offering 12 month price targets forRoivant Sciences Ltd - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Roivant Sciences Ltd - Dist in the past 3 months.

Technical Score

By Trading Central

11 / 11.18Support & Resistance

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentiment

By Acuity

13 / 345 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.